» Articles » PMID: 14583457

Li-Fraumeni and Related Syndromes: Correlation Between Tumor Type, Family Structure, and TP53 Genotype

Overview
Journal Cancer Res
Specialty Oncology
Date 2003 Oct 30
PMID 14583457
Citations 164
Authors
Affiliations
Soon will be listed here.
Abstract

A database has been created to collect information on families carrying a germ-line mutation in the TP53 gene and on families affected with Li-Fraumeni syndromes [Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like syndrome (LFL)]. Data from the published literature have been included. The database is available online at http://www.iarc.fr/p53, as part of the IARC TP53 Database. The analysis of the 265 families/individuals that have been included thus far has revealed several new findings. In classical LFS families with a germ-line TP53 mutation (83 families), the mean age of onset of breast cancer was significantly lower than in LFS families (16 families) without a TP53 mutation (34.6 versus 42.5 years; P = 0.0035). In individuals with a TP53 mutation, a correlation between the genotype and phenotype was found. Brain tumors were associated with missense TP53 mutations located in the DNA-binding loop that contact the minor groove of DNA (P = 0.01), whereas adrenal gland carcinomas were associated with missense mutations located in the loops opposing the protein-DNA contact surface (P = 0.003). Finally, mutations likely to result in a null phenotype (absence of the protein or loss of function) were associated with earlier onset brain tumors (P = 0.004). These observations have clinical implications for genetic testing and tumor surveillance in LFS/LFL families.

Citing Articles

Sex Disparities in P53 Regulation and Functions: Novel Insights for Personalized Cancer Therapies.

Cardano M, Buscemi G, Zannini L Cells. 2025; 14(5).

PMID: 40072091 PMC: 11898824. DOI: 10.3390/cells14050363.


Personalized screening strategies for R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriers.

Galante P, Guardia G, Pisani J, Sandoval R, Barros-Filho M, Gifoni A Lancet Reg Health Am. 2025; 42:100982.

PMID: 39895904 PMC: 11787607. DOI: 10.1016/j.lana.2024.100982.


Decoding the mechanisms behind second primary cancers.

Zeng M, Lin A, Jiang A, Qiu Z, Zhang H, Chen S J Transl Med. 2025; 23(1):115.

PMID: 39856672 PMC: 11762917. DOI: 10.1186/s12967-025-06151-9.


Meta-EA: a gene-specific combination of available computational tools for predicting missense variant effects.

Katsonis P, Lichtarge O Nat Commun. 2025; 16(1):159.

PMID: 39746940 PMC: 11696468. DOI: 10.1038/s41467-024-55066-4.


New Germline TP53 Variant Detected After Radiotherapy-Induced Angiosarcoma of the Chest Wall in a Previously Treated Breast Cancer Patient: A Case Report and Review of Li-Fraumeni Syndrome and Radiotherapy-Induced Sarcoma.

Bianca Lopes David B, Silva S, Dinoa V, Diniz T, Pereira E, Bustamante C Case Rep Oncol Med. 2024; 2024:6640468.

PMID: 39734593 PMC: 11671632. DOI: 10.1155/crom/6640468.